linjc16/ctgov huggingface dataset:
Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer

Study Overview
=================
Brief Summary
-----------------
Safety and Efficacy of Ginsenoside Rg3 in Combination with First-line Chemotherapy in Advanced Gastric Cancer.The purpose of this study is to assess the safety of Ginsenoside Rg3 in advanced gastric cancer, and whether it improves the efficacy of first-line chemotherapy.

Official Title
-----------------
Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer

Conditions
-----------------
Self Efficacy

Intervention / Treatment
-----------------
* Drug: Ginsenoside Rg3 plus First-line Chemotherapy
* Drug: First-line Chemotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed informed consent form Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1; Histologically or cytologically confirmed gastric cancer; At least have one measurable disease(according to RECIST, Response Evaluation Criteria in Solid Tumors ) Life expectancy of at least 3 months; Exclusion Criteria: Received any prior treatment including Ginsenoside Rg3; Active or uncontrolled infection; Concurrent treatment with an investigational agent or participation in another therapeutic clinical trial; Pregnant or lactating women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: experimental<br>Ginsenoside Rg3 plus First-line Chemotherapy | Drug: Ginsenoside Rg3 plus First-line Chemotherapy<br>* Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression<br>|
| Active Comparator: Active Comparator<br>First-line Chemotherapy | Drug: First-line Chemotherapy<br>* XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Progression-free survival (PFS) |  | 1 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Objective Response Rate (ORR) |  | 1 year | 
| Overall Survival (OS) |  | 3 year |
Thyroid Cancer Database

Study Overview
=================
Brief Summary
-----------------
Thyroid cancer database collects clinical and laboratory data from patients with a thyroid tumor who received radioactive Iodine treatment. This database only records information based on patients' medical files in a structured manner. Thyroid database is used for retrospective non-interventional research projects.

Official Title
-----------------
Prospective and Retrospective Thyroid Cancer Database

Conditions
-----------------
Patients With a Thyroid Tumor Who Received Radioactive Iodine Treatment

Intervention / Treatment
-----------------
* Other: Radioactive Iodine treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with a thyroid tumor (metastatic or not) patients who received radioactive Iodine treatment. age >= 18 Exclusion Criteria: Objection to collect medical data records

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Radioactive Iodine treatment for thyroid cancer<br> | Other: Radioactive Iodine treatment<br>* Patients with a thyroid tumor who received radioactive Iodine treatment.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient survival | Overall survival and evolution over years | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of patient and treatment characteristics | Collection of patient and treatment characteristics over years, to set up prospective and retrospective studies | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Thyroid cancer, Iodine treatment
Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) Patients

Study Overview
=================
Brief Summary
-----------------
in this study the investigators will measure the colchicine trough levels in 80 FMF patients taking stable doses of colchicine

Detailed Description
-----------------
80 FMF patients will enroll: 20 taking 1 mg colchicine a day 20 taking 1.5 mg colchicine a day 20 taking 2 mg colchicine a day 20 taking 2.5 mg colchicine a day one blood sample for trough colchicine levels will be taken. response to treatment, colchicine side effects and anthropometric data will be collected.

Official Title
-----------------
Measurement of Colchicine Levels in the Serum of FMF Patients

Conditions
-----------------
FMF, Colchicine Resistance, Colchicine Toxicity

Intervention / Treatment
-----------------
* Diagnostic Test: colchicine level measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: constant colchicine levels

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| FMF patients<br>fmf patients under a constant colchicine dose | Diagnostic Test: colchicine level measurement<br>* levels of colchicine will be measured in FMF patients taking colchicine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| colchicine levels | the trough level of colchicine in the serum | a single measurement under a constant dosage at visit 1 (time=0, recruitment) |
BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy-

Study Overview
=================
Brief Summary
-----------------
This study is designed to compare the efficacy and safety of BRL49653C versus pioglitazone and placebo.

Official Title
-----------------
Clinical Evaluation of Rosiglitazone Malate (BRL49653C) in Patients With Type 2 Diabetes Mellitus (Monotherapy) - Double-Blind Comparative Study of Rosiglitazone Maleate vs. Pioglitazone Hydrochloride and Placebo -

Conditions
-----------------
Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: Rosiglitazone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Type 2 diabetes mellitus. Managed by diet therapy. Must have adequate blood, liver and kidney function. Exclusion criteria: Serious cardiovascular disease or serious hepatic disease.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Rosiglitazone|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c change from baseline at Week 28. |  | 28 Weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy variables (changes from baseline in FPG, fasting insulin, HOMA-IR and HOMA-beta) at stipulated date in each treatment group. |  | 28 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
rosiglitazone, vandia, Type 2 diabetes mellitus, diabetes;
Enabling Independent Living by Expanding Access to Home-Based Pulmonary Rehabilitation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test an existing home-based pulmonary rehab program with the addition of video chat and a capability of a Spanish version.

Detailed Description
-----------------
The purpose of this research is to test video chat on a computer tablet that is used for Pulmonary Rehabilitation. We are interested in learning patients' thoughts on how easy or difficult video chat is to use and the translation to Spanish and the feed back from Spanish speaking patients .

Official Title
-----------------
Enabling Independent Living by Expanding Access to Home-Based Pulmonary Rehabilitation

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Behavioral: Video Chat


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients must be ≥ 40 years old. Patients mist have a diagnosis of GOLD stage II, III, or IV COPD documented by pulmonary function testing. Patients must be a current or previous smoker with at least 10 pack-years of cigarette smoking. Additional Inclusion Criteria to test Spanish version of system: Be a native Spanish speaker. Exclusion Criteria: Patients with a high likelihood of being lost to follow-up or contact (patients with active chemical dependency). Patients planning to move out of the state or who are not living in the healthcare area. Patients with an inability to provide good data or follow commands (patients who are disoriented, have a severe neurologic or psychiatric condition).

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Intervention<br>This is a small study to assess the usability of video conferencing. A total of 10 patients will be enrolled, 5 of which will be Spanish speakers. All patients will test the video conferencing. | Behavioral: Video Chat<br>* Video chat with health coach using a computer tablet.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative Interview | A Qualitative Interview will be conducted over the phone asking about the video chat experience. | Week 1 |
S8600-S9031-S9333-A, Study of DNA in Samples From Patients With Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment. PURPOSE: This research trial studies DNA in samples from patients with acute myeloid leukemia.

Detailed Description
-----------------
OBJECTIVES: To identify differentially methylated regions (DMRs) associated with overall survival (OS) of acute myeloid leukemia (AML) patients with normal cytogenetics. To develop and evaluate in an independent validation set a prognostic score for OS based on the identified DMR. To determine whether the prognostic score can group patients into risk groups based on OS. OUTLINE: Archived blood or bone marrow samples are analyzed for DNA methylation alterations by CHARM array-based genome assay. Each patient's clinical data is also collected.

Official Title
-----------------
S8600-S9031-S9333-A, Identification of Differentially Methylated Genomic Regions That Are Prognostically Significant in AML

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: DNA methylation analysis
* Genetic: gene expression analysis
* Genetic: microarray analysis
* Other: laboratory biomarker analysis
* Other: medical chart review


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: De novo acute myeloid leukemia (AML) patients with normal cytogenetics treated with curative therapy who survived at least 28 days after therapy started Samples will be taken from the following studies: SWOG-8600, SWOG-9031, SWOG-9333, SWOG-9500, SWOG-S9918, SWOG-S0106, and SWOG-S0112 Blood or marrow specimens can be used PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: See Disease Characteristics

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: DNA methylation analysis|nan|
|Genetic: gene expression analysis|nan|
|Genetic: microarray analysis|nan|
|Other: laboratory biomarker analysis|nan|
|Other: medical chart review|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of DMRs associated with OS |  | immediate | 
| Development and evaluation of a prognostic score of OS based on DMRs identified |  | immediate | 
| Prognostic score able to group AML patients into risk groups |  | immediate | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
untreated adult acute myeloid leukemia
Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation

Study Overview
=================
Brief Summary
-----------------
Study to determine if a user-friendly medical abortion regimen using letrozole and misoprostol is safe and acceptable.

Official Title
-----------------
Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation: A Pilot Study to Evaluate the Safety and Acceptably of a User-friendly Regimen

Conditions
-----------------
Pregnancy

Intervention / Treatment
-----------------
* Drug: 30 mg letrozole followed by 800 mcg misoprostol


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnancy ≤ 63 days gestational age by ultrasound seeking termination of pregnancy Pregnancy visible on ultrasound Speaks English or Spanish Willing and able to return for follow-up appointment Exclusion Criteria: People with gestations > 63 days gestational age Confirmed or suspected ectopic pregnancy or undiagnosed adnexal mass Pregnancy of unknown location IUD or contraceptive implant in place History of allergy to letrozole or misoprostol Unable to return for clinic-based follow-up Currently breastfeeding Twin or multiple pregnancy History of liver disease or abnormal liver function

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Letrozole followed by misoprostol<br>There is only one arm in this study. | Drug: 30 mg letrozole followed by 800 mcg misoprostol<br>* 30 mg letrozole on day 1 followed by 800 mcg misoprostol on day 3<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety Profile of medical abortion regimen | To evaluate the safety profile of a user-friendly letrozole-misoprostol regimen. | 2 weeks |
Uveal Melanoma and Brachytheraphy: Long-term Outcomes.

Study Overview
=================
Brief Summary
-----------------
This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival in patients affected by uveal melanoma and undergoing Ru-106 plaque brachytherapy between February 2011 and March 2020

Official Title
-----------------
Long-term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy

Conditions
-----------------
106 Ruthenium Plaque Brachytherapy, Uveal Melanoma

Intervention / Treatment
-----------------
* Radiation: 106 Ruthenium plaque brachytherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age older than 40 years diagnosis of uveal melanoma Exclusion Criteria: age older than 80 years No diagnosis of uveal melanoma

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: 106 Ruthenium plaque brachytherapy|All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To evaluate long-term outcomes in patients underwent brachytherapy for uveal melanoma | To investigate the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival | Mean follow-up was 4 years (3 months-9 years) |
Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia

Study Overview
=================
Brief Summary
-----------------
The investigators would like to know the association of gene polymorphisms and metabolic adversities in clozapine-treated patients with schizophrenia in Taiwan.

Detailed Description
-----------------
The atypical antipsychotics, such as olanzapine, risperidone, quetiapine, and ziprasidone, are effective in treating both the positive and negative symptoms in schizophrenia (Kelleher et al., 2002). However, atypical antipsychotics have been linked to several forms of morbidity, including obesity, hyperlipidemia, and type 2 diabetes mellitus (DM) (Bergman and Ader, 2005; Jin et al., 2004; Melkersson and Dahl, 2004). Compared with the general population, life expectancy in schizophrenic patients is shorter by as much as 20%, attributable to higher rates of suicide, accidental deaths, and natural causes such as cardiovascular disease and DM (Harris and Barraclough, 1998). Several studies have suggested that these metabolic abnormalities may lead to a greater vulnerability to cardiovascular disease and thus may contribute to the excessive mortality among schizophrenic patients.

Official Title
-----------------
Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia

Conditions
-----------------
Schizophrenia, Schizoaffective Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: fulfilled DSM-IV criteria of schizophrenia or schizoaffective disorder 18-65 year of age receiving clozapine for at least 6 months Exclusion Criteria: diabetes mellitus patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
schizophrenia, schizoaffective disorder
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

Study Overview
=================
Brief Summary
-----------------
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.

Detailed Description
-----------------
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus the PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer. We aim to enrolled 100 patients in this study, the primary endpoint was PFS.

Official Title
-----------------
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer ( Poseidon Study）

Conditions
-----------------
Non-small Cell Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology RET Fusion Positive First Diagnosis and Treatment Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody Exclusion Criteria: - Patients received antitumor treatment before Patients with contraindication of chemotherapy Pregnant or breast feeding women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Progression free survival time | may 2020- may 2021 (1 year) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ORR | Overal response rate | may 2020- may 2021 (1 year) | 
| OS | Overall survival time | may 2020- may 2021 (1 year) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PD-L1 ;RET Fusion Lung Cancer Patients